- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02264977
Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms
August 10, 2022 updated by: W.L.Gore & Associates
Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (Branched TAG® Device) in the Treatment of Aortic Arch Aneurysms
The purpose of this study is to assess the early feasibility of the use of the GORE® TAG® Thoracic Branch Endoprosthesis to treat aneurysms involving the aortic arch
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The GORE® TAG® Thoracic Endoprosthesis (TAG® Device) received premarket approval (PMA) for use in endovascular aneurysm repair of the descending thoracic aorta (DTA) on 23-Mar-2005 under P040043, and design changes that resulted in the conformable GORE® TAG® Thoracic Endoprosthesis (CTAG) received premarket approval for the treatment of aneurysms of the DTA on 23-Aug-2011 (P040043/S039).
The TAG® Device and CTAG are intended to exclude an aneurysm from the blood circulation in patients diagnosed with DTA aneurysms.
However, endovascular treatment options for patients with aortic arch aneurysms are limited as current stent graft technology would require coverage of aortic arch vessels.
This prompted the creation of the GORE® TAG® Thoracic Branch Endoprosthesis (previously known as Branched TAG® Device), which was being evaluated under IDE G130120 for Zone 2 aneurysms when this clinical investigation was initiated to evaluate the GORE® TAG® Thoracic Branch Endoprosthesis for the treatment of Zone 0 and Zone 1 aneurysms of the aortic arch.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305-5407
- Leland Stanford Junior University
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Rochester
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- The Hitchcock Foundation (Dartmouth Hitchcock Medical Center)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital at University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Univerisity of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Presence of aortic aneurysm involving the aortic arch deemed to warrant surgical repair which requires proximal graft placement in Zone 0 or Zone 1:
- Fusiform (≥ 55 mm), or
- Fusiform (>2 times native aortic diameter), or
- Saccular (no diameter criteria)
- Subject is considered a high risk candidate for conventional open surgical repair at the discretion of the Investigator
- Age ≥18 years at time of informed consent signature
- Subject is capable of complying with protocol requirements, including follow-up
- Informed Consent Form (ICF) is signed by Subject or legal representative
Must have appropriate proximal aortic landing zone, defined as:
- Must require placement of the proximal extent of the Aortic Component in Zone 0 or Zone 1 for exclusion of the lesion
- Acceptable proximal landing zone outer curvature length for the required device
- Landing zone inner diameters between 16-48 mm in Zone 1 Subjects and 24-48mm in Zone 0 Subjects
- Landing zone, which must include either the brachiocephalic or left common carotid native ostium, cannot be aneurysmal, heavily calcified, or heavily thrombosed
Must have appropriate distal aortic landing zone, defined as:
- Outer curvature length must be ≥2cm proximal to the celiac artery
- Aortic inner diameters between 16-48 mm (diameter must be between 16-42mm if using distal TAG® Device extension)
- Landing zone cannot be aneurysmal, heavily calcified, or heavily thrombosed
- Landing zone in native aorta or previously implanted GORE® TAG® Device
Must have appropriate target branch vessel landing zone, defined as:
- Length of ≥3 cm proximal to first major branch vessel if using Aortic Component with 8 mm portal diameter, or length of ≥2.5 cm proximal to first major branch vessel if using Aortic Component with 12 mm portal diameter (required for Zone 0 Subjects)
- Target branch vessel inner diameters of 6-15 mm if using Aortic Component with 8mm portal diameter, or inner diameters of 11-18 mm if using Aortic Component with 12mm portal diameter (required for Zone 0 Subjects)
- Target branch vessel landing zone must be in native aorta that cannot be aneurysmal, heavily calcified, or heavily thrombosed
Exclusion Criteria:
- Concomitant aneurysm/disease of the ascending aorta, or abdominal aorta requiring repair
- Previous endovascular repair of the ascending aorta
- Previous endovascular repair of the DTA with a non-Gore device
- Surgery within 30 days of treatment
- Infected aorta
- Dissection of the aorta
- Intramural hematoma of the aortic arch or DTA without aneurysm
- Life expectancy <2 years
- Myocardial infarction or stroke within 6 weeks prior to treatment
- Patient has a systemic infection and may be at increased risk of endovascular graft infection
- Pregnant female at time of informed consent signature
- Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome
- Participation in another drug or medical device study within one year of study enrollment
- Known history of drug abuse within one year of treatment
- Significant thrombus or atheroma in the aortic arch
- Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access
- Planned coverage of celiac artery
- Patient has known sensitivities or allergies to the device materials
- Patient has known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
- Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin
- Diameter taper outside of the device sizing range between proximal and distal landing zones of aorta and the inability to use additional devices of different diameters to compensate for the taper
- Mycotic aneurysm
- Persistent refractory shock (systolic blood pressure <90 mm Hg)
- Patient has body habitus or other medical condition which prevents adequate visualization of the aorta
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Branched TAG® Device
Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Successful Study Device Access
Time Frame: During treatment procedure (day 0)
|
Access to the aneurysm and target landing zone location is obtained via conventional vascular access and endovascular techniques.
|
During treatment procedure (day 0)
|
Number of Participants With Successful Study Device Deployment
Time Frame: During treatment procedure (day 0)
|
Absence of deployment failure will be considered a successful deployment.
Deployment failure will be considered the failure of any Branched TAG® Device component (Aortic Component, Aortic Extender, or SB Component) to be released from the delivery catheter resulting in a serious adverse event (SAE) due to mechanical failure or use error.
|
During treatment procedure (day 0)
|
Number of Participants With Primary Procedural Side Branch Patency
Time Frame: At conclusion of the treatment procedure (day 0)
|
The presence of forward flow through the implanted Side Branch Component into the target branch vessel.
|
At conclusion of the treatment procedure (day 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With 1 Month Side Branch Primary Patency Assessed by an Independent Core Lab
Time Frame: 1 Month
|
1 Month
|
|
Number of Participants Without 1 Month Device Related Endoleaks Assessed by an Independent Core Lab
Time Frame: 1 Month
|
Device-related endoleaks are defined as the presence of contrast within the aneurysm sac originating from the junction between any Branched TAG® Device component and the landing zone (Type IA or IB) or the junction between the Aortic Component and either the Side Branch Component or the Aortic Extender (Type III).
|
1 Month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2015
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
March 1, 2022
Study Registration Dates
First Submitted
October 8, 2014
First Submitted That Met QC Criteria
October 8, 2014
First Posted (Estimate)
October 15, 2014
Study Record Updates
Last Update Posted (Actual)
September 14, 2022
Last Update Submitted That Met QC Criteria
August 10, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSB 11-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aneurysm of Aortic Arch
-
University Hospital MuensterRecruitingAortic Arch Aneurysm | Aortic Arch | Dissection of Aortic Arch | Triple BranchGermany
-
Baptist Health South FloridaWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch AneurysmUnited States
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
Gustavo OderichWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Aortic Arch DissectionUnited States
-
Fuji Systems CorporationAvaniaActive, not recruitingAortic Aneurysm | Aortic Dissection | Aortic Arch Aneurysm | Aortic Arch; Aneurysm, DissectingGermany, Netherlands
-
Endospan Ltd.CompletedAortic Arch AneurysmSwitzerland, Italy, New Zealand
-
Centre Hospitalier Universitaire de Saint EtienneCompletedAortic Arch AneurysmFrance, Netherlands
-
Timothy Chuter, MDRecruiting
-
Darren Schneider, M.D.RecruitingEndovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent GraftsAortic Aneurysm, Thoracic | Aortic Aneurysm, Thoracoabdominal | Aortic Dissection, ThoracoabdominalUnited States
-
Cook Research IncorporatedRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Chronic Aortic DissectionDenmark, France, Germany
Clinical Trials on GORE® TAG® Thoracic Branch Endoprosthesis
-
W.L.Gore & AssociatesActive, not recruitingAortic Aneurysm, Thoracic | Aorta; LesionUnited States
-
W.L.Gore & AssociatesCompletedAortic Aneurysm, ThoracicUnited States
-
W.L.Gore & AssociatesActive, not recruitingAortic Aneurysm, Thoracic | Aorta, LesionUnited States, Japan
-
W.L.Gore & AssociatesCompletedAortic Aneurysm, ThoracicUnited States
-
University Hospital PadovaNot yet recruiting
-
W.L.Gore & AssociatesCompletedType B Aortic DissectionUnited States
-
W.L.Gore & AssociatesCompletedAortic Aneurysm, ThoracicUnited States
-
W.L.Gore & AssociatesCompletedThoracic Aortic Aneurysm | Thoracic Aortic Dissection | Thoracic Aorta Injury
-
W.L.Gore & AssociatesCompletedAneurysmUnited States
-
W.L.Gore & AssociatesCompletedAortic Diseases | Aortic Aneurysm, Thoracic | Penetrating Ulcer | Descending Thoracic Aortic Dissection | Aorta Thoracic; Traumatic RuptureFrance